» Articles » PMID: 14770308

Expression Patterns of Erythropoietin and Its Receptor in the Developing Midbrain

Overview
Date 2004 Feb 11
PMID 14770308
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

The expression patterns of erythropoietin (EPO) and its receptor (EPOR) were investigated in the midbrain and in adjacent parts of the synencephalon and hindbrain of embryonic C57Bl mice. On embryonic (E) day 8 (E8), virtually all neuroepithelial cells expressed EPOR. After neural tube closure, subsets of these cells downregulated EPOR. In contrast, radial glial cells were EPOR-immunolabeled from E11 onwards. Simultaneously, subpopulations of early developing neurons upregulated EPO and expressed HIF-1, known to transcriptionally activate EPO. Three-dimensional reconstructions revealed subpopulations of EPO-expressing neurons: (1) in the trigeminal mesencephalic nucleus (TMN), (2) at the rostral transition of the midbrain and synencephalon, (3) in the basal plate of the midbrain, (4) in the trigeminal motor nucleus, and (5) in the trigeminal principal sensory nucleus. In the rostral midbrain and synencephalon, EPO-immunoreactive neurons were attached to EPOR-expressing radial glial cells. The identity of radial glial cells was proven by their immunoreactivity for antibodies against astrocyte-specific glutamate transporter, brain lipid-binding protein, and nestin. From E12.5 onwards EPOR was downregulated in radial glial cells. Viable neurons of the TMN continued to express EPO and upregulated EPOR. Our findings provide new evidence that components of the EPO system are present in distinct locations of the embryonic brain and, by interactions between neurons and radial glial cells as well as among clustered TMN neurons, may contribute to its morphogenesis. Whether the observed expression patterns of EPO and EPOR may reflect EPO-mediated trophic and/or antiapoptotic effects on neurons is discussed.

Citing Articles

Erythropoietin as a Neuroprotective Drug for Newborn Infants: Ten Years after the First Use.

Perrone S, Lembo C, Gironi F, Petrolini C, Catalucci T, Corbo G Antioxidants (Basel). 2022; 11(4).

PMID: 35453337 PMC: 9031072. DOI: 10.3390/antiox11040652.


The Effect of Erythropoietin and Its Derivatives on Ischemic Stroke Therapy: A Comprehensive Review.

Ma Y, Zhou Z, Yang G, Ding J, Wang X Front Pharmacol. 2022; 13:743926.

PMID: 35250554 PMC: 8892214. DOI: 10.3389/fphar.2022.743926.


Oligodendrocyte Development and Implication in Perinatal White Matter Injury.

Motavaf M, Piao X Front Cell Neurosci. 2021; 15:764486.

PMID: 34803612 PMC: 8599582. DOI: 10.3389/fncel.2021.764486.


Neonatal administration of erythropoietin attenuates cognitive deficits in adult rats following placental insufficiency.

Robinson S, Winer J, Kitase Y, Brigman J, Jantzie L J Neurosci Res. 2021; 100(12):2112-2126.

PMID: 33611820 PMC: 10097461. DOI: 10.1002/jnr.24815.


Endogenous erythropoietin signaling regulates migration and laminar positioning of upper-layer neurons in the developing neocortex.

Constanthin P, Contestabile A, Petrenko V, Quairiaux C, Salmon P, Huppi P Development. 2020; 147(19).

PMID: 32764029 PMC: 7561482. DOI: 10.1242/dev.190249.